In ZINC since | Heavy atoms | Benign functionality |
---|---|---|
October 5th, 2005 | 26 | No |
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2; CPD001227202; Prednisone; SAM002264641
53-03-2; Prednisone; Prestwick_405
CPD001227202; Prednisone; SAM002264641
D00473; Deltasone (TN); Meticorten (TN); Prednisone (USP); Prednisone monohydrate; Rayos (TN)
Dehydrocortisone;Prednisona [INN-Spanish];Prednisonum [INN-Latin]
Deltasone, Liquid Pred, Orasone, Adasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Prednisona [INN-Spanish];Prednisonum [INN-Latin];Dehydrocortisone
prednisona; prednisone; prednisonum
Pregna-1,4-diene-3,11,20-trione monohydrate, 17,21-dihydroxy-
pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy-
Pregna-1,4-diene-3,11,20-trione, 17,21-hydroxy-
Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
---|---|---|---|---|---|---|---|---|---|---|
Ref Reference (pH 7) | 1.41 | 4.54 | -15.88 | 2 | 5 | 0 | 92 | 358.434 | 2 | ↓ |
Note Type | Comments | Provided By |
---|---|---|
Molecular_Solubility | 3.446 | Bitter DB |
ALOGPS_SOLUBILITY | 1.11e-01 g/l | DrugBank-approved |
MP | 253 - 255 | Enamine Building Blocks |
MP | 253...255 | Enamine Building Blocks |
purity | 9.500000000000000e+001 | Enamine Building Blocks Enamine Building Blocks |
Purity | 99% | APIChem |
mechanism | ACTH antagonist | IBScreen Bioactives |
mechanism | ACTH secretion inhibitor | IBScreen Bioactives |
biological_use | Antiinflammatory | IBScreen Bioactives |
mechanism | Calcium mobilizer | IBScreen Bioactives |
mechanism | Corticosteroid | IBScreen Bioactives IBScreen Bioactives |
Patent Database Links | EP1229034; EP1514877; EP1527772; EP1537858; EP1538164; EP1543839; EP1557173; EP1580188; EP1607103; EP1611879; EP1616569; EP1616572; EP1629835; EP1637126; EP1645281; EP1649857; EP1661557; EP1688146; EP1717247; EP1731140; EP1754472; EP1762248; EP1832605; EP | ChEBI |
Therapy | glucocorticoid | SMDC Pharmakon |
Target | Glucocorticoid Receptor | Selleck Chemicals |
mechanism | Gluconeogenesis promoter | IBScreen Bioactives |
mechanism | Glycogen deposition inhibitor | IBScreen Bioactives |
H phrase | H361: Suspected of damaging fertility or the unborn child | Acros Organics |
biological_use | Immunosuppressive | IBScreen Bioactives IBScreen Bioactives |
PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : P-7859 | NIH Clinical Collection via PubChem |
Target | Others | Selleck Chemicals |
P phrase | P201: Obtain special instructions before use; P202: Do not handle until all safety precautions have been read and understood; P281: Use personal protective equipment as required; P308 + P313: IF exposed or concerned: Get medical advice/attention | Acros Organics |
mechanism | Phosphorus mobilizer | IBScreen Bioactives |
R phrase | R63: Possible risk of harm to the unborn child. | Acros Organics |
PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: P-7859 | NIH Clinical Collection via PubChem |
Hazard | XN: Harmful | Acros Organics |